Terms: = Breast cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Prognosis
154 results:
1. Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/arf.
Sui XY; Ma XY; Hou Y; Cao SW; Wang ZQ; Jia LJ; Fan L; Shao ZM; Zhang WJ
Cell Biol Toxicol; 2024 Apr; 40(1):24. PubMed ID: 38653919
[TBL] [Abstract] [Full Text] [Related]
2. Novel 2 Gene Signatures Associated With breast cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis.
Ibrahim A; Toss MS; Alsaleem M; Makhlouf S; Atallah N; Green AR; Rakha EA
Mod Pathol; 2024 Feb; 37(2):100403. PubMed ID: 38104894
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
4. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
5. cdkn2a was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model.
Wan H; Yang X; Sang G; Ruan Z; Ling Z; Zhang M; Liu C; Hu X; Guo T; He J; Liu D; Pei J
Aging (Albany NY); 2023 Oct; 15(20):11244-11267. PubMed ID: 37857018
[TBL] [Abstract] [Full Text] [Related]
6. The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Zhu C; Du Y; Huai Q; Fang N; Xu W; Yang J; Li X; Zhang Y; Zhang X; Dai H; Li X; Wang H; Dai Y
Reprod Sci; 2024 Feb; 31(2):532-549. PubMed ID: 37798609
[TBL] [Abstract] [Full Text] [Related]
7. Diagnosis and prognosis of Thyroid cancer by Immune-related Genes.
Li J; Li Z; Zhao P
Am J Clin Oncol; 2024 Jan; 47(1):1-10. PubMed ID: 37779238
[TBL] [Abstract] [Full Text] [Related]
8. Adverse Crosstalk between Extracellular Matrix Remodeling and Ferroptosis in Basal breast cancer.
Desterke C; Cosialls E; Xiang Y; Elhage R; Duruel C; Chang Y; Hamaï A
Cells; 2023 Aug; 12(17):. PubMed ID: 37681908
[TBL] [Abstract] [Full Text] [Related]
9. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China.
Zhang C; Wu H; Xu G; Xu Y; Ma W; Li Z; Zhang J
BMC Cancer; 2023 Jun; 23(1):506. PubMed ID: 37271825
[TBL] [Abstract] [Full Text] [Related]
10. OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating p16 expression.
Zhou T; Wu Y; Qian D; Tang H; Liu X; Qiu J; Wang D; Hong W; Meng X; Zheng Q
Pathol Res Pract; 2023 Jul; 247():154571. PubMed ID: 37257246
[TBL] [Abstract] [Full Text] [Related]
11. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
12. MTA1 as negative prognostic marker in vulvar carcinoma.
Wanka G; Jueckstock J; Wild CM; Vattai A; Fürst S; Heidegger HH; Kuhn C; Schmoeckel E; Jeschke U; Dannecker C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6191-6201. PubMed ID: 36689059
[TBL] [Abstract] [Full Text] [Related]
13. Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1.
Chen M; Pan Y; Liu H; Ning F; Lu Q; Duan Y; Gan X; Lu S; Hou H; Zhang M; Tian Y; Lash GE
Cell Oncol (Dordr); 2023 Jun; 46(3):571-587. PubMed ID: 36580262
[TBL] [Abstract] [Full Text] [Related]
14. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in breast cancer.
Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
[TBL] [Abstract] [Full Text] [Related]
15. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.
Li S; He J; Liao X; He Y; Chen R; Chen J; Hu S; Sun J
Cell Biol Toxicol; 2023 Aug; 39(4):1641-1655. PubMed ID: 36112263
[TBL] [Abstract] [Full Text] [Related]
16. cdkn2a-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract] [Full Text] [Related]
17. Analysis of recurrent molecular alterations in phyllodes tumour of breast: insights into prognosis and pathogenesis.
Tsang JY; Shao Y; Poon IK; Ni YB; Kwan JS; Chow C; Shea KH; Tse GM
Pathology; 2022 Oct; 54(6):678-685. PubMed ID: 35691725
[TBL] [Abstract] [Full Text] [Related]
18. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
[TBL] [Abstract] [Full Text] [Related]
19. The
Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
[TBL] [Abstract] [Full Text] [Related]
20. A seven-autophagy-related gene signature for predicting the prognosis of differentiated thyroid carcinoma.
Li C; Yuan Q; Xu G; Yang Q; Hou J; Zheng L; Wu G
World J Surg Oncol; 2022 Apr; 20(1):129. PubMed ID: 35459137
[TBL] [Abstract] [Full Text] [Related]
[Next]
